Drug intelligence / Profile preview

ethinylestradiol + drospirenone + Selmevit

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

Ethinylestradiol + drospirenone + Selmevit appears to refer to a combination of two pharmaceutical agents—ethinylestradiol (a synthetic estrogen) and drospirenone (a synthetic progestin with antiandrogenic and antimineralocorticoid properties)—with "Selmevit," which is a multivitamin/mineral dietary supplement. Ethinylestradiol and drospirenone are commonly used together as an oral contraceptive for the prevention of pregnancy, as well as for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea in women[5][3][7]. Their mechanism involves suppression of ovulation via inhibition of gonadotropins, alteration of cervical mucus, and endometrial changes unfavorable to implantation[5][3]. Drospirenone also acts as an antimineralocorticoid and antiandrogen[5]. "Selmevit" is not a pharmaceutical drug but rather a multivitamin/mineral supplement; it does not have direct pharmacological action relevant to contraception or hormonal therapy. The combination described here is not recognized as a standard or approved fixed-dose product in major regulatory databases.

02

Targets

MR (Mineralocorticoid receptor)ER (Estrogen receptor)PR (Progesterone receptor)AR (Adrenergic receptors)

Beyond the preview

Go deeper on ethinylestradiol + drospirenone + Selmevit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethinylestradiol + drospirenone + Selmevit.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call